Table 2. Patient demographics and baseline characteristics.
Author Name | Julio Rosenstock 2021 [19] | Dominik Dahl 2022 [23] | Juan Pablo Frias 2021 [24] | Bernhard Ludvik 2021 [25] | Juan Pablo Frias 2020 [26] | Juan Pablo Frias 2018 [27] | |||||||
Tirzepatide | Placebo | Tirzepatide | Placebo | Tirzepatide | Semaglutide | Tirzepatide | Degludec | Tirzepatide | Placebo | Tirzepatide | Placebo | Dulaglutide | |
No. of patient | 5mg: 121 10mg: 121 15mg: 121 | 115 | 5mg: 116 10mg: 119 15mg: 120 | 120 | 5mg: 470 10mg: 469 15mg: 470 | 469 | 5mg: 358 10mg: 360 15mg: 359 | 360 | 15mg: 28 | 26 | 5mg:55 10mg:51 15mg:53 | 51 | 54 |
Gender (Male) | 5mg: 56 10mg: 72 15mg: 63 | 56 | 5mg: 61 10mg: 72 15mg: 65 | 66 | 5mg: 205 10mg: 238 15mg: 214 | 225 | 5mg: 200 10mg: 195 15mg: 194 | 213 | 15mg: 16 | 12 | 5mg:34 10mg:30 15mg:22 | 29 | 24 |
Gender (Female) | 5mg: 65 10mg: 49 15mg: 58 | 59 | 5mg: 55 10mg: 47 15mg: 55 | 54 | 5mg: 265 10mg: 231 15mg: 256 | 244 | 5mg: 158 10mg: 165 15mg: 165 | 147 | 15mg:12 | 14 | 5mg:21 10mg:21 15mg:31 | 22 | 30 |
Mean Age | 5mg: 54 10mg:56 15mg: 53 | 54 | 5mg: 62 10mg: 60 15mg: 61 | 60 | 5mg: 56 10mg: 57 15mg: 56 | 57 | 5mg: 57 10mg: 57 15mg: 57 | 58 | 15mg: 55 | 56 | 5mg:58 10mg:56 15mg:56 | 56 | 58 |
Baseline HbA1C | 5mg:7.97 10mg:7.90 15mg: 7.85 | 8.05 | 5mg: 8.3 10mg: 8.4 15mg: 8.2 | 8.37 | 5mg: 8.32 10mg: 8.3 15mg: 8.3 | 8.25 | 5mg: 8.17 10mg: 8.18 15mg: 8.21 | 8.12 | 15mg: 8.5 | 8.2 | 5mg:8.2 10mg: 8.2 15mg: 8.1 | 8 | 8.1 |
Baseline BMI | 5mg:32.2 10mg:32.2 15mg:31.5 | 31.7 | 5mg: 34 10mg: 33 15mg: 33 | 33.2 | 5mg: 33.8 10mg:34.3 15mg:34.5 | 34.2 | 5mg:33.6 10mg:33.4 15mg:33.7 | 33.4 | 15mg: 32 | 32.5 | 5mg:33 10mg:32 15mg: 32 | 32 | 32 |
Duration of Diabetes (years) | 5mg: 4.6 10mg: 4.9 15mg: 4.8 | 4.5 | 5mg: 14 10mg: 13 15mg: 14 | 12.9 | 5mg:9.1 10mg:8.4 15mg:8.7 | 8.3 | 5mg:8.5 10mg:8.4 15mg: 8.5 | 8.1 | 15mg: 8.2 | 8.8 | 5mg: 8.9 10mg:7.9 15mg: 8.5 | 8.6 | 9.3 |